Key result
Thrombolytic therapy, particularly with low-dose and slow-infusion rates of tissue plasminogen activator, has emerged as an effective and safe alternative to surgery for prosthetic valve thrombosis.
Why the study?
What are the current treatment options and their comparative efficacies for prosthetic heart valve thrombosis?
What are the current treatment options and their comparative efficacies for prosthetic heart valve thrombosis?
This review highlights that low-dose, slow-infusion thrombolysis is emerging as an excellent alternative to traditional surgical therapy for prosthetic valve thrombosis.
Answers are grounded in this paper and cite their sources.
May support individualized decisions in prosthetic valve thrombosis; leaves open need for randomized trials before practice change.
Prosthetic heart valve thrombosis (PVT) is a rare but serious complication with high morbidity and mortality. The optimal treatment of the PVT is controversial and depends on thrombus location and size, the patient's functional class, the risk of surgery or thrombolysis, and the clinician's experience. Although surgical therapy has been the traditional therapeutic approach, studies with low-dose and slow-infusion rates of thrombolytic agents have revealed excellent results. This article reviews the various treatment options in patient with PVT.
No takes yet. Share an insight, caveat, or question.
Biteker et al. (2015) conducted a review in Prosthetic heart valve thrombosis. Thrombolytic therapy vs. Surgery was evaluated. Thrombolytic therapy, particularly with low-dose and slow-infusion rates of tissue plasminogen activator, has emerged as an effective and safe alternative to surgery for prosthetic valve thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: